170 related articles for article (PubMed ID: 17912239)
1. Mucin impedes cytotoxic effect of 5-FU against growth of human pancreatic cancer cells: overcoming cellular barriers for therapeutic gain.
Kalra AV; Campbell RB
Br J Cancer; 2007 Oct; 97(7):910-8. PubMed ID: 17912239
[TBL] [Abstract][Full Text] [Related]
2. Mucin overexpression limits the effectiveness of 5-FU by reducing intracellular drug uptake and antineoplastic drug effects in pancreatic tumours.
Kalra AV; Campbell RB
Eur J Cancer; 2009 Jan; 45(1):164-73. PubMed ID: 19046630
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of KL-6/MUC1 glycosylation limits aggressive progression of pancreatic cancer.
Xu HL; Zhao X; Zhang KM; Tang W; Kokudo N
World J Gastroenterol; 2014 Sep; 20(34):12171-81. PubMed ID: 25232251
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the O-glycan elongation limits MUC1 incorporation to cell membrane of human endometrial carcinoma cells.
Porowska H; Paszkiewicz-Gadek A; Anchim T; Wolczynski S; Gindzienski A
Int J Mol Med; 2004 Mar; 13(3):459-64. PubMed ID: 14767580
[TBL] [Abstract][Full Text] [Related]
5. Investigating the role of mucin in the delivery of nanoparticles to cellular models of human cancer disease: an in vitro study.
Alkholief M; Campbell RB
Nanomedicine; 2016 Jul; 12(5):1291-302. PubMed ID: 26961466
[TBL] [Abstract][Full Text] [Related]
6. Permanent exposure of mucin-secreting HT-29 cells to benzyl-N-acetyl-alpha-D-galactosaminide induces abnormal O-glycosylation of mucins and inhibits constitutive and stimulated MUC5AC secretion.
Hennebicq-Reig S; Lesuffleur T; Capon C; De Bolos C; Kim I; Moreau O; Richet C; Hémon B; Recchi MA; Maës E; Aubert JP; Real FX; Zweibaum A; Delannoy P; Degand P; Huet G
Biochem J; 1998 Aug; 334 ( Pt 1)(Pt 1):283-95. PubMed ID: 9693131
[TBL] [Abstract][Full Text] [Related]
7. Antiadhesive character of mucin O-glycans at the apical surface of corneal epithelial cells.
Sumiyoshi M; Ricciuto J; Tisdale A; Gipson IK; Mantelli F; Argüeso P
Invest Ophthalmol Vis Sci; 2008 Jan; 49(1):197-203. PubMed ID: 18172093
[TBL] [Abstract][Full Text] [Related]
8. Effect of benzyl-alpha-GalNAc, an inhibitor of mucin glycosylation, on cancer-associated antigens in human colon cancer cells.
Huang J; Byrd JC; Yoon WH; Kim YS
Oncol Res; 1992; 4(11-12):507-15. PubMed ID: 1284381
[TBL] [Abstract][Full Text] [Related]
9. E-selectin binding by pancreatic tumor cells is inhibited by cancer sera.
Sawada T; Ho JJ; Chung YS; Sowa M; Kim YS
Int J Cancer; 1994 Jun; 57(6):901-7. PubMed ID: 7515860
[TBL] [Abstract][Full Text] [Related]
10. Access to peptide regions of a surface mucin (MUC1) is reduced by sialic acids.
Ho JJ; Cheng S; Kim YS
Biochem Biophys Res Commun; 1995 May; 210(3):866-73. PubMed ID: 7539263
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of reactivity of anti-MUC1 core protein antibody and killing activity of anti-MUC1 cytotoxic T cells by deglycosylation of target tissues or cells.
Hinoda Y; Takahashi T; Hayashi T; Suwa T; Makiguchi Y; Itoh F; Adachi M; Imai K
J Gastroenterol; 1998 Apr; 33(2):164-71. PubMed ID: 9605944
[TBL] [Abstract][Full Text] [Related]
12. GalNAc-alpha-O-benzyl inhibits NeuAcalpha2-3 glycosylation and blocks the intracellular transport of apical glycoproteins and mucus in differentiated HT-29 cells.
Huet G; Hennebicq-Reig S; de Bolos C; Ulloa F; Lesuffleur T; Barbat A; Carrière V; Kim I; Real FX; Delannoy P; Zweibaum A
J Cell Biol; 1998 Jun; 141(6):1311-22. PubMed ID: 9628888
[TBL] [Abstract][Full Text] [Related]
13. Benzyl-N-acetyl-alpha-D-galactosaminide inhibits the sialylation and the secretion of mucins by a mucin secreting HT-29 cell subpopulation.
Delannoy P; Kim I; Emery N; De Bolos C; Verbert A; Degand P; Huet G
Glycoconj J; 1996 Oct; 13(5):717-26. PubMed ID: 8909998
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of mucin synthesis by benzyl-alpha-GalNAc in KATO III gastric cancer and Caco-2 colon cancer cells.
Byrd JC; Dahiya R; Huang J; Kim YS
Eur J Cancer; 1995; 31A(9):1498-505. PubMed ID: 7577079
[TBL] [Abstract][Full Text] [Related]
15. Diverse glycosylation of MUC1 and MUC2: potential significance in tumor immunity.
Irimura T; Denda K; Iida Si; Takeuchi H; Kato K
J Biochem; 1999 Dec; 126(6):975-85. PubMed ID: 10578046
[TBL] [Abstract][Full Text] [Related]
16. N-acetylgalactosamine glycosylation of MUC1 tandem repeat peptides by pancreatic tumor cell extracts.
Nishimori I; Perini F; Mountjoy KP; Sanderson SD; Johnson N; Cerny RL; Gross ML; Fontenot JD; Hollingsworth MA
Cancer Res; 1994 Jul; 54(14):3738-44. PubMed ID: 8033093
[TBL] [Abstract][Full Text] [Related]
17. Differential glycosylation of MUC1 in tumors and transfected epithelial and lymphoblastoid cell lines.
Poland PA; Kinlough CL; Rokaw MD; Magarian-Blander J; Finn OJ; Hughey RP
Glycoconj J; 1997 Jan; 14(1):89-96. PubMed ID: 9076518
[TBL] [Abstract][Full Text] [Related]
18. 4-Methylumbelliferone Decreases the Hyaluronan-rich Extracellular Matrix and Increases the Effectiveness of 5-Fluorouracil.
Yoshida E; Kudo D; Nagase H; Suto A; Shimoda H; Suto S; Kakizaki I; Endo M; Hakamada K
Anticancer Res; 2018 Oct; 38(10):5799-5804. PubMed ID: 30275202
[TBL] [Abstract][Full Text] [Related]
19. Purification and characterization of a human pancreatic adenocarcinoma mucin.
Khorrami AM; Choudhury A; Andrianifahanana M; Varshney GC; Bhattacharyya SN; Hollingsworth MA; Kaufman B; Batra SK
J Biochem; 2002 Jan; 131(1):21-9. PubMed ID: 11754731
[TBL] [Abstract][Full Text] [Related]
20. Biochemical characterization of the soluble form of tumor antigen MUC1 isolated from sera and ascites fluid of breast and pancreatic cancer patients.
Beatty P; Hanisch FG; Stolz DB; Finn OJ; Ciborowski P
Clin Cancer Res; 2001 Mar; 7(3 Suppl):781s-787s. PubMed ID: 11300473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
